Substituted 7-amino-5-thio-thiazolo[4,5-d]pyrimidines as potent and selective antagonists of the fractalkine receptor (CX3CR1).
暂无分享,去创建一个
V. Ivanov | L. Vares | E. Jerning | G. Nordvall | A. Kers | D. Turek | D. Sohn | Å. Malmberg | S. Karlström | T. Rein | Can Slivo | R. Johansson | M. Claesson | Andreas Hettman | Kristofer Åhlin | Y. Lo-Alfredsson | Galina Bessidskaia | Charlotte Ahlgen | Colin A Ray | P. H. Svensson | Carl Petersson
[1] P. Prusis,et al. Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds , 2010, Xenobiotica; the fate of foreign compounds in biological systems.
[2] John J. M. Wiener,et al. Recent advances in the design of cathepsin S inhibitors. , 2010, Current topics in medicinal chemistry.
[3] Dongmei Wang,et al. Discovery and optimization of novel 3-piperazinylcoumarin antagonist of chemokine-like factor 1 with oral antiasthma activity in mice. , 2010, Journal of medicinal chemistry.
[4] Kuang-Yu Liu,et al. Transcriptional profiling reveals developmental relationship and distinct biological functions of CD16+ and CD16- monocyte subsets , 2009, BMC Genomics.
[5] N. Hewitt,et al. Comparison of intrinsic metabolic clearance in fresh and cryopreserved human hepatocytes , 2009, Xenobiotica; the fate of foreign compounds in biological systems.
[6] M. Waring. Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability. , 2009, Bioorganic & medicinal chemistry letters.
[7] R. Leurs,et al. Nonpeptidergic Allosteric Antagonists Differentially Bind to the CXCR2 Chemokine Receptor , 2009, Journal of Pharmacology and Experimental Therapeutics.
[8] L. Di,et al. In vitro solubility assays in drug discovery. , 2008, Current drug metabolism.
[9] Brian A. Chauder,et al. Discovery of bioavailable 4,4-disubstituted piperidines as potent ligands of the chemokine receptor 5 and inhibitors of the human immunodeficiency virus-1. , 2008, Journal of medicinal chemistry.
[10] Franco Lombardo,et al. Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds , 2008, Drug Metabolism and Disposition.
[11] M. Kikuyama,et al. Adsorptive Depletion of Elevated Proinflammatory CD14+CD16+DR++ Monocytes in Patients With Inflammatory Bowel Disease , 2008, The American Journal of Gastroenterology.
[12] E. Novellino,et al. Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. , 2008, Journal of medicinal chemistry.
[13] R. Austin,et al. Evaluation of a series of bicyclic CXCR2 antagonists. , 2008, Bioorganic & medicinal chemistry letters.
[14] D. Busch,et al. Chemokine Fractalkine Mediates Leukocyte Recruitment to Inflammatory Endothelial Cells in Flowing Whole Blood: A Critical Role for P-Selectin Expressed on Activated Platelets , 2007, Circulation.
[15] T. Bueters,et al. Combined approach for high-throughput preparation and analysis of plasma samples from exposure studies. , 2007, Rapid communications in mass spectrometry : RCM.
[16] R. Austin,et al. SAR studies on thiazolo[4,5-d]pyrimidine based CXCR2 antagonists involving a novel tandem displacement reaction. , 2007, Bioorganic & medicinal chemistry letters.
[17] R. Ransohoff,et al. Inflammatory Cell Migration into the Central Nervous System: A Few New Twists on an Old Tale , 2007, Brain pathology.
[18] L. Ziegler‐Heitbrock,et al. The CD14+ CD16+ blood monocytes: their role in infection and inflammation , 2007, Journal of leukocyte biology.
[19] Andrea Rosario Beccari,et al. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. , 2006, Pharmacology & therapeutics.
[20] F. Tacke,et al. Migratory fate and differentiation of blood monocyte subsets. , 2006, Immunobiology.
[21] John Unitt,et al. Hit-to-Lead studies: the discovery of potent, orally bioavailable thiazolopyrimidine CXCR2 receptor antagonists. , 2006, Bioorganic & medicinal chemistry letters.
[22] B. Isaac,et al. Syk Is Required for Monocyte/Macrophage Chemotaxis to CX3CL1 (Fractalkine)1 , 2005, The Journal of Immunology.
[23] Alireza Minagar,et al. Blood-brain barrier disruption in multiple sclerosis , 2003, Multiple sclerosis.
[24] Bryan Roberts,et al. Hit-to-lead studies: the discovery of potent, orally bioavailable triazolethiol CXCR2 receptor antagonists. , 2003, Bioorganic & medicinal chemistry letters.
[25] F. Fahrenholz,et al. The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. , 2003, Blood.
[26] W. Metz,et al. Unraveling the chemistry of chemokine receptor ligands. , 2003, Chemical reviews.
[27] Ismael Zamora,et al. pH-Dependent Bidirectional Transport of Weakly Basic Drugs Across Caco-2 Monolayers: Implications for Drug–Drug Interactions , 2003, Pharmaceutical Research.
[28] Richard J. Miller,et al. Chemokine receptors: signposts to brain development and disease , 2003, Nature Reviews Neuroscience.
[29] R. Horuk,et al. Chemokines, chemokine receptors and small-molecule antagonists: recent developments. , 2002, Trends in pharmacological sciences.
[30] T. Kaufman,et al. A simple protocol for the one pot synthesis of chiral secondary benzylic alcohols by catalytic enantioselective reduction of aromatic ketones , 2002 .
[31] O. Yoshie,et al. Dual Functions of Fractalkine/CX3C Ligand 1 in Trafficking of Perforin+/Granzyme B+ Cytotoxic Effector Lymphocytes That Are Defined by CX3CR1 Expression , 2002, The Journal of Immunology.
[32] A. Proudfoot. Chemokine receptors: multifaceted therapeutic targets , 2002, Nature Reviews Immunology.
[33] I. Forbes,et al. CCR2B receptor antagonists: conversion of a weak HTS hit to a potent lead compound. , 2000, Bioorganic & Medicinal Chemistry Letters.
[34] I. Charo,et al. Molecular Uncoupling of Fractalkine-mediated Cell Adhesion and Signal Transduction , 1999, The Journal of Biological Chemistry.
[35] R. Maki,et al. Chemokines and chemokine receptors in the CNS: a possible role in neuroinflammation and patterning. , 1999, TIPS - Trends in Pharmacological Sciences.
[36] T M Handel,et al. Solution structure and dynamics of the CX3C chemokine domain of fractalkine and its interaction with an N-terminal fragment of CX3CR1. , 1999, Biochemistry.
[37] W. Streit,et al. Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[38] E. Corey,et al. Reduction of Carbonyl Compounds with Chiral Oxazaborolidine Catalysts: A New Paradigm for Enantioselective Catalysis and a Powerful New Synthetic Method. , 1998, Angewandte Chemie.
[39] G. Fingerle-Rowson,et al. Selective depletion of CD14+ CD16+ monocytes by glucocorticoid therapy , 1998, Clinical and experimental immunology.
[40] T. Schall,et al. Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion , 1997, Cell.
[41] J. Gutiérrez-Ramos,et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation , 1997, Nature.
[42] T. Shioiri,et al. A Practical Method for Asymmetric Borane Reduction of Prochiral Ketones Using Chiral Amino Alcohols and Trimethyl Borate , 1997 .
[43] Wei Wang,et al. A new class of membrane-bound chemokine with a CX3C motif , 1997, Nature.
[44] R. Eddy,et al. The orphan G-protein-coupled receptor-encoding gene V28 is closely related to genes for chemokine receptors and is expressed in lymphoid and neural tissues. , 1995, Gene.
[45] C. Harrington,et al. Lowry protein assay containing sodium dodecyl sulfate in microtiter plates for protein determinations on fractions from brain tissue. , 1990, Analytical biochemistry.
[46] P. Ramachandran,et al. Chiral synthesis via organoboranes. 14. Selective reductions. 41. Diisopinocampheylchloroborane, an exceptionally efficient chiral reducing agent , 1988 .
[47] O. Miyashita,et al. Synthesis and coronary vasodilating activity of 2-substituted adenosines. , 1975, Chemical & pharmaceutical bulletin.